Results 121 to 130 of about 13,821 (239)

Myasthenia Gravis and Thymoma

Muscle &Nerve, EarlyView.
ABSTRACT Thymoma is the most common tumor of the anterior mediastinum. Approximately 20%–30% of patients with a thymoma develop myasthenia gravis (MG), and an additional one third may possess positive acetylcholine receptor (AChR) antibodies without MG.
Benjamin Claytor, Lukas Delasos, Daniel P. Raymond, Erik Seroogy, Jason Lempel, Yuebing Li   +5 more
wiley   +1 more source

The life cycle of tertiary lymphoid structures in pancreatic cancer-a window of opportunity for immunotherapy. [PDF]

Front Immunol
Chen Y, Xiao Y, Zhang T, Wang X.
europepmc   +1 more source

Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of ‘‐mabs’?

The Journal of Pathology, EarlyView.
Abstract Prostate cancer (PCa) is the second most common type of neoplasm, currently treated with a variety of therapeutic agents. Although advances in treatment over the past decade have improved overall survival, patients with advanced PCa eventually progress from hormone‐sensitive PCa to metastatic castration‐resistant PCa.
Giuseppe Schepisi, Irene Torresan, Emilio Francesco Giunta, Sara Bleve, Nicole Brighi, Elisa Tassinari, Sofia Zanuccoli, Maria Concetta Cursano, Cristian Lolli   +8 more
wiley   +1 more source

The biological characteristics of tertiary lymphoid structures in head and neck cancer. [PDF]

Front Immunol
Bai S, Wei Y, Liu F, Sun H, Zeng X, Zhang P.   +5 more
europepmc   +1 more source

Granzyme K: A new frontier in systemic lupus erythematosus

Rheumatology &Autoimmunity, EarlyView.
The role of Granzyme K in the pathogenesis of systemic lupus erythematosus and its clinical translational significance. Abstract Systemic lupus erythematosus (SLE) is a complex autoimmune disorder driven by dysregulated adaptive and innate immunity and aberrant complement activity.
Zhongyu Chen, Yunjing Pu, Peihui Yang, Qinghuan Zhu, Haojun Long, Danqi Deng   +5 more
wiley   +1 more source

Therapeutic potential of tertiary lymphoid structures in breast cancer (Review). [PDF]

Mol Med Rep
Zhu L, Li M, Liu F, Gao F.
europepmc   +1 more source

Photo‐responsive carbon dots for pyroptosis‐mediated anti‐tumor application

Responsive Materials, EarlyView.
Photo‐responsive CDs generate ROS to induce tumor cell pyroptosis, thereby stimulating antitumor immunity. Abstract Pyroptosis refers to a kind of lytic programmed cell death, characterized by the release of pro‐inflammatory cytokines during the process. Owing to its immune response stimulation ability, pyroptosis has garnered considerable attention in
Lingyun Li, Xue Wu, Zekun Yan, Jun Wu, Caishi Huang, Songnan Qu   +5 more
wiley   +1 more source

Four‐dimensional immuno‐mechanobiomaterials: Dynamic material cues that program host response to prevent fibrosis and enable regeneration

VIEW, EarlyView.
Dynamic immuno‐mechanobiomaterials with time‐programmed mechanical adaptation orchestrate host responses through precise mechanotransduction and immune‐stromal regulation. These adaptive biomaterials minimize mechanical mismatch, attenuate the forign dy response and fibrosis, promote angiogenesis and controlled extracellular matrix remodeling, and ...
Gobinath Vellapalayam Manoharan, Kathirvel Ayyaswamy, Parthasarathy Vellaichamy, Nagarajan Deivanayagam Pillai, Rithik Gobinath   +4 more
wiley   +1 more source

Tertiary lymphoid structures in breast cancer: formation, immune functions and clinical implications. [PDF]

Front Immunol
Dong W, Ai S, Shen X, Yao Y.
europepmc   +1 more source

Biomarkers Predictive of Immunotherapy Efficacy in Head and Neck Squamous Cell Carcinoma: Current Insights and Future Perspectives

World Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT With the approval of immunotherapies by regulatory bodies, head and neck squamous cell carcinoma (HNSCC) treatment has been revolutionized, and anti‐programmed cell death‐1 (anti‐PD‐1) agents are now the standard for platinum‐resistant recurrent/metastatic HNSCC.
Xiao‐Tong Yan, Zhao‐Hong An, Chang‐Ming An   +2 more
wiley   +1 more source